TY - JOUR
T1 - Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
AU - Kadowaki, Takashi
AU - Yamauchi, Toshimasa
AU - Kubota, Naoto
AU - Hara, Kazuo
AU - Ueki, Kohjiro
AU - Tobe, Kazuyuki
PY - 2006/7/3
Y1 - 2006/7/3
N2 - Adiponectin is an adipokine that is specifically and abundantly expressed in adipose tissue and directly sensitizes the body to insulin. Hypoadiponectinemia, caused by interactions of genetic factors such as SNPs in the Adiponectin gene and environmental factors causing obesity, appears to play an important causal role in insulin resistance, type 2 diabetes, and the metabolic syndrome, which are linked to obesity. The adiponectin receptors, AdipoR1 and AdipoR2, which mediate the antidiabetic metabolic actions of adiponectin, have been cloned and are downregulated in obesity-linked insulin resistance. Upregulation of adiponectin is a partial cause of the insulin-sensitizing and antidiabetic actions of thiazolidinediones. Therefore, adiponectin and adiponectin receptors represent potential versatile therapeutic targets to combat obesity-linked diseases characterized by insulin resistance. This Review describes the pathophysiology of adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.
AB - Adiponectin is an adipokine that is specifically and abundantly expressed in adipose tissue and directly sensitizes the body to insulin. Hypoadiponectinemia, caused by interactions of genetic factors such as SNPs in the Adiponectin gene and environmental factors causing obesity, appears to play an important causal role in insulin resistance, type 2 diabetes, and the metabolic syndrome, which are linked to obesity. The adiponectin receptors, AdipoR1 and AdipoR2, which mediate the antidiabetic metabolic actions of adiponectin, have been cloned and are downregulated in obesity-linked insulin resistance. Upregulation of adiponectin is a partial cause of the insulin-sensitizing and antidiabetic actions of thiazolidinediones. Therefore, adiponectin and adiponectin receptors represent potential versatile therapeutic targets to combat obesity-linked diseases characterized by insulin resistance. This Review describes the pathophysiology of adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.
UR - http://www.scopus.com/inward/record.url?scp=33745834319&partnerID=8YFLogxK
U2 - 10.1172/JCI29126
DO - 10.1172/JCI29126
M3 - 総説
C2 - 16823476
AN - SCOPUS:33745834319
SN - 0021-9738
VL - 116
SP - 1784
EP - 1792
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 7
ER -